Company intelligence / Profile preview
ARCE Therapeutics
Taipei, Taiwanarcetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Currently conducting a Phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome, which started on March 1, 2025.
- Therapeutic areas
- OncologyOther
- Modalities
- CAR-T cell therapyCAR-NK cell therapycellular immunotherapygene-modified cellular immunotherapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Seeking partners for U.S. and global clinical development
Beyond the preview
Go deeper on ARCE Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARCE Therapeutics.